Laekna, Inc. (HKG:2105)

Market Cap	5.60B +40.8%
Revenue (ttm)	118.76M
Net Income	-255.19M
EPS	-0.66
Shares Out	420.55M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,028,600
Average Volume	2,677,562
Open	13.12
Previous Close	13.31
Day's Range	13.12 - 14.05
52-Week Range	10.30 - 23.50
Beta	-1.04
RSI	39.72
Earnings Date	May 13, 2026

About Laekna

Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis in the People’s Republic of China, the United States of America, and South Korea. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer, and PD-1/PD-L1 drug-resistant solid tumors; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 83
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2105

Financial Performance

Financial numbers in CNY